| scholarly article | Q13442814 |
| MDMA | Q69488 |
| review article | Q7318358 |
| P356 | DOI | 10.1080/02791072.1986.10472362 |
| P698 | PubMed publication ID | 2880944 |
| P2093 | author name string | Nichols DE | |
| P2860 | cites work | Effects of the phenethylamine derivatives, BL-3912, fenfluramine, and Sch-12679, in rats trained with LSD as a discriminative stimulus | Q42257219 |
| Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes | Q48948400 | ||
| A pharmacologic comparison of 3,4-methylenedioxyamphetamine and LSD in the chronic spinal dog | Q50850162 | ||
| MDA: An agent that produces stimulus effects similar to those of 3,4-DMA, LSD and cocaine | Q51847575 | ||
| Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. | Q52260167 | ||
| Further investigation of the discriminative stimulus properties of MDA. | Q52275177 | ||
| MDA: a psychoactive agent with dual stimulus effects. | Q52276451 | ||
| Phenylakylamines with potential psychotherapeutic utility. 1. 2-Amino-1-(2,5-dimethoxy-4-methylphenyl)butane | Q52308083 | ||
| Increased Lever Pressing for Amphetamine After Pimozide in Rats: Implications for a Dopamine Theory of Reward | Q52313595 | ||
| Stereospecific requirements for hallucinogenesis. | Q53898878 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 305-313 | |
| P577 | publication date | 1986-10-01 | |
| P1433 | published in | Journal of Psychoactive Drugs | Q6295808 |
| P1476 | title | Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens | |
| P478 | volume | 18 |
| Q47777762 | (±)-MDMA and its enantiomers: potential therapeutic advantages of R(-)-MDMA. |
| Q42177467 | 1-(1,3-Benzodioxol-5-yl)butan-1-one |
| Q33540473 | 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. |
| Q28270011 | 3,4-Methylenedioxyamphetamine (MDA) analogues exhibit differential effects on synaptosomal release of 3H-dopamine and 3H-5-hydroxytryptamine |
| Q40624643 | 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy"): pharmacology and toxicology in animals and humans |
| Q34377051 | 3,4-Methylenedioxymethamphetamine counteracts akinesia enantioselectively in rat rotational behavior and catalepsy |
| Q34437998 | 3,4-methylenedioxymethamphetamine (MDMA): a review |
| Q24602762 | 3,4-methylenedioxymethamphetamine (MDMA): current perspectives |
| Q64070251 | A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy |
| Q38105567 | A case of drug-facilitated sexual assault involving 3,4-methylenedioxy-methylamphetamine |
| Q34674320 | Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions |
| Q35105559 | Acute Psychological and Neurophysiological Effects of MDMA in Humans |
| Q40518413 | Acute and long-term effects of ecstasy |
| Q44777848 | Acute methylenedioxymethamphetamine administration: effects on local cerebral blood flow and glucose utilisation in the Dark Agouti rat. |
| Q38962662 | Altered Insula Connectivity under MDMA. |
| Q35095703 | Altered states: the clinical effects of Ecstasy. |
| Q34102744 | An exploration of the history and controversies surrounding MDMA and MDA. |
| Q40301274 | Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers |
| Q37622283 | Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. |
| Q34290962 | Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats. |
| Q41694692 | Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners |
| Q43855515 | Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine). |
| Q34535259 | Clinical applications of hallucinogens: A review |
| Q34675455 | Clinical features and management of intoxication due to hallucinogenic drugs |
| Q28243881 | Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices |
| Q56763257 | Colorimetric detection and chromatographic analyses of designer drugs in biological materials: a comprehensive review |
| Q34300503 | Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine |
| Q55007454 | Crime and Violence among MDMA Users in the United States. |
| Q46540907 | Cytotoxic effects of 3,4-methylenedioxy-N-alkylamphetamines, MDMA and its analogues, on isolated rat hepatocytes |
| Q57176236 | Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine |
| Q28279302 | Determination of amphetamine, methamphetamine and amphetamine-derived designer drugs or medicaments in blood and urine |
| Q35965775 | Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats |
| Q53087323 | Discriminative stimulus and locomotor effects of para-substituted and benzofuran analogs of amphetamine. |
| Q37196303 | Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations |
| Q91305817 | Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects |
| Q34560372 | Drug discrimination studies with MDMA and amphetamine |
| Q54296991 | Ecstasy abuse and dependence among adolescents and young adults: applicability and reliability of DSM-IV criteria. |
| Q44125648 | Ecstasy and drug consumption patterns: a Canadian rave population study |
| Q58419076 | Ecstasy and sleep disturbance: Progress towards elucidating a role for the circadian system |
| Q40540791 | Ecstasy intoxication: the toxicological basis for treatment |
| Q44418655 | Ecstasy: a review of scientific literature about MDMA |
| Q34675745 | Effects of 3,4-methylenedioxymethamphetamine on socioemotional feelings, authenticity, and autobiographical disclosure in healthy volunteers in a controlled setting |
| Q27329826 | Effects of MDMA Injections on the Behavior of Socially-Housed Long-Tailed Macaques (Macaca fascicularis) |
| Q34368013 | Effects of Repeated Administration of 3,4-methylenedioxymethamphetamine (MDMA) on Avoidance Memory and Cell Density in Rats' Hippocampus. |
| Q43698610 | Enantio-selective cognitive and brain activation effects of N-ethyl-3,4-methylenedioxyamphetamine in humans |
| Q73508114 | Enantioselective determination of 3,4-methylene-dioxymethamphetamine and two of its metabolites in human urine by cyclodextrin-modified capillary zone electrophoresis |
| Q44136657 | Enantioselective metabolism of the designer drugs 3,4-methylenedioxymethamphetamine ('ecstasy') and 3,4-methylenedioxyethylamphetamine ('eve') isomers in rat brain and blood |
| Q44541736 | Enantioselective quantitation of the ecstasy compound (R)- and (S)-N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma and urine |
| Q34035262 | Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys |
| Q51932115 | Evidence for a hallucinogen dependence syndrome developing soon after onset of hallucinogen use during adolescence. |
| Q42784959 | Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4- methylenedioxypyrovalerone |
| Q37940942 | GHB and synthetic cathinones: clinical effects and potential consequences |
| Q39292988 | Hallucinogens in Drug Discrimination |
| Q34359604 | Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research |
| Q47620618 | Hydrothermally synthesized zinc oxide nanorods incorporated on lab-on-paper device for electrochemical detection of recreational drug. |
| Q57976339 | Identification of an acetal derivative of the piperonyl methyl ketone in tablets seized for suspected drug trafficking |
| Q34434069 | Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes |
| Q73755207 | Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs |
| Q34325119 | Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes |
| Q36421673 | Intimate insight: MDMA changes how people talk about significant others |
| Q21091087 | Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans |
| Q43842107 | Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. |
| Q26799231 | Legal highs: staying on top of the flood of novel psychoactive substances |
| Q51082984 | Long-lasting effects of (+/-)3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system function in humans. |
| Q37149027 | MDMA (3,4-Methylenedioxymethamphetamine) Analogues as Tools to Characterize MDMA-Like Effects: An Approach to Understand Entactogen Pharmacology |
| Q45959723 | MDMA (Ecstasy) decreases the number of neurons and stem cells in embryonic cortical cultures. |
| Q48095503 | MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors |
| Q43729285 | MDMA induces Per1, Per2 and c-fos gene expression in rat suprachiasmatic nuclei |
| Q41278263 | MDMA produces stimulant-like conditioned locomotor activity |
| Q36643639 | MDMA use and neurocognition: a meta-analytic review |
| Q91839166 | MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials |
| Q36151338 | MDMA-like behavioral effects of N-substituted piperazines in the mouse |
| Q46674939 | Mental disorders in current and former heavy ecstasy (MDMA) users |
| Q33810318 | Metabolites of MDMA induce oxidative stress and contractile dysfunction in adult rat left ventricular myocytes. |
| Q55043421 | Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation. |
| Q51976287 | N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine (MBDB): its properties and possible risks. |
| Q28240337 | Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice |
| Q48413494 | Neurochemical and behavioural characterisation of alkoxyamphetamine derivatives in rats |
| Q26770106 | Neuroimaging in moderate MDMA use: A systematic review |
| Q37233828 | Neurotoxic thioether adducts of 3,4-methylenedioxymethamphetamine identified in human urine after ecstasy ingestion |
| Q44865152 | Neurotoxicity of methamphetamine and methylenedioxymethamphetamine |
| Q34497492 | Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? |
| Q34507084 | Non-linear pharmacokinetics of MDMA ('ecstasy') in humans |
| Q34521723 | Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. |
| Q36209983 | Party drugs: properties, prevalence, patterns, and problems |
| Q38351502 | Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences? |
| Q39026719 | Predicting the Abuse Liability of Entactogen-Class, New and Emerging Psychoactive Substances via Preclinical Models of Drug Self-administration |
| Q48684860 | Product ion mass spectra of amphetamine-type substances, designer analogues, and ketamine using ultra-performance liquid chromatography/tandem mass spectrometry |
| Q47963200 | Progress and promise for the MDMA drug development program |
| Q36721893 | Psychedelic and entactogenic drugs in the treatment of depression |
| Q34493217 | Psychedelic medicine: a re-emerging therapeutic paradigm |
| Q21090031 | Psychedelics and the human receptorome |
| Q64960952 | Quantification of 3,4-methylenedioxymetamphetamine and its metabolites in plasma and urine by gas chromatography with nitrogen-phosphorus detection. |
| Q77737753 | Quantitation of N-ethyl-3,4-methylenedioxyamphetamine and its major metabolites in human plasma by high-performance liquid chromatography and fluorescence detection |
| Q92891791 | Receptor-Enriched Analysis of functional connectivity by targets (REACT): A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA |
| Q48221705 | Reckless behaviour related to the use of 3,4-methylenedioxymethamphetamine (ecstasy): apropos of a fatal accident during car-surfing |
| Q38555431 | Recreational MDMA use in Sydney: a profile of 'Ecstacy' users and their experiences with the drug |
| Q36012329 | Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice |
| Q34565898 | Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: are intravenous self-administration experiments relevant to MDMA neurotoxicity? |
| Q48273339 | Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice |
| Q44149198 | Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats |
| Q44385002 | Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination |
| Q46571097 | Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse |
| Q46936069 | Simultaneous determination of new thioamphetamine designer drugs in plasma by capillary electrophoresis coupled with mass spectrometry |
| Q33217225 | Simultaneous determination of ten amphetamine designer drugs in human whole blood by capillary electrophoresis with diode array detection |
| Q42873932 | Simultaneous separation and confirmation of amphetamine and related drugs in equine plasma by non‐aqueous capillary‐electrophoresis‐tandem mass spectrometry |
| Q44457569 | Synthetic drugs of abuse, the second generation (designer drugs). 1. Amphetamine and other arylalkane amines |
| Q33940156 | Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study |
| Q47640031 | The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant |
| Q37928627 | The Drug Information and Monitoring System (DIMS) in the Netherlands: implementation, results, and international comparison |
| Q49241289 | The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports |
| Q47807643 | The History of MDMA as an Underground Drug in the United States, 1960-1979. |
| Q37925507 | The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis |
| Q30341737 | The Neuropsychopharmacology and Toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). |
| Q59341209 | The Varieties of the Psychedelic Experience: A Preliminary Study of the Association Between the Reported Subjective Effects and the Binding Affinity Profiles of Substituted Phenethylamines and Tryptamines |
| Q46970778 | The acute and long-term neurotoxic effects of MDMA on marble burying behaviour in mice |
| Q38937390 | The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants? |
| Q28236333 | The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans |
| Q35754068 | The neuropharmacology of prolactin secretion elicited by 3,4-methylenedioxymethamphetamine ("ecstasy"): a concurrent microdialysis and plasma analysis study |
| Q28361466 | The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs |
| Q35146115 | The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). |
| Q36734781 | The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review |
| Q28373367 | Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ('Ecstasy') |
| Q35175998 | Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans |
| Q28752119 | What's in a label? Ecstasy sellers' perceptions of pill brands |
| Q38687081 | Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective |
Search more.